A major strength of this study is a large sample of hospitalized T2DM patients receiving CSII therapy was included and the monitoring of capillary blood glucose and tailoring of insulin dosage was conducted following the standard protocol by trained doctors and nurses. The gene discussed is INS; the disease is type 2 diabetes mellitus.